Berubicin receives FDA Orphan Drug status for gliomas

The Directors: Steven Artandi and Eric Winer on how looming policy changes “reverberate” through oncology
“Even when funding gets restored and if the H-1B visa threat doesn’t materialize, it creates an environment where especially young people become uncertain.”

With major leadership changes, grant disruptions and terminations, and a stoked distrust in science, Steven Artandi, the director of Stanford Cancer Center, worries that young investigators will feel disenchanted by the U.S. research atmosphere and take their work and study elsewhere.

October 10, 2025

Vol.51 No.37

By Claire Marie Porter and Paul Goldberg

Guest Editorial

ASCO and Google Cloud set forth a vision for using AI to modernize health care and advance oncology

Cancer care is evolving at an unprecedented pace. Practitioners feel the mounting pressures daily: rising cancer rates—particularly in younger patients—a growing population of older cancer survivors, rapid growth in new care and treatment options, and navigating heightened fiscal constraints and uncertainty.

October 10, 2025

Vol.51 No.37

By Clifford A. Hudis and Thomas Kurian

KRAS pioneer and Stephenson Prize winner Frank McCormick aims to prevent all KRAS cancers with a pill

In 1988, Frank McCormick learned with the rest of the field that more than 90% of patients with pancreatic cancer have a mutation in the Kirsten rat sarcoma viral gene.

Lazarex Cancer Foundation set to close its doors Dec. 31
Can health nonprofits survive in the current environment?

As every non-profit organization knows, it is our obligation to be purpose-driven. Most NPO founders and the people who work for them have been thrown into this space as a result of life experiences. It is our passion rather than a job to simply collect a paycheck.

October 10, 2025

Vol.51 No.37

By Erin Miller

Cancer Policy

ASCO report shows decrease in the number of oncologists relative to aging population

A report by the American Society of Clinical Oncology points to a growing challenge in cancer care access driven by a widening gap between the number of available oncologists and increasing patient demand.

October 10, 2025

Vol.51 No.37

By Claire Marie Porter

Cancer Policy

Trump backs off the 100% pharma tariffs ultimatum

President Donald Trump had threatened pharmaceutical companies with a 100% tariff, with an ultimatum set for Oct. 1.

October 10, 2025

Vol.51 No.37

By Claire Marie Porter

Berubicin receives FDA Orphan Drug status for gliomas

YOU MAY BE INTERESTED IN

The Directors: Steven Artandi and Eric Winer on how looming policy changes “reverberate” through oncology
“Even when funding gets restored and if the H-1B visa threat doesn’t materialize, it creates an environment where especially young people become uncertain.”

ASCO and Google Cloud set forth a vision for using AI to modernize health care and advance oncology

KRAS pioneer and Stephenson Prize winner Frank McCormick aims to prevent all KRAS cancers with a pill

Lazarex Cancer Foundation set to close its doors Dec. 31
Can health nonprofits survive in the current environment?

ASCO report shows decrease in the number of oncologists relative to aging population

Trump backs off the 100% pharma tariffs ultimatum

Renew today!

Subscriber content

Never miss an issue!

Login

Berubicin receives FDA Orphan Drug status for gliomas

YOU MAY BE INTERESTED IN

The Directors: Steven Artandi and Eric Winer on how looming policy changes “reverberate” through oncology“Even when funding gets restored and if the H-1B visa threat doesn’t materialize, it creates an environment where especially young people become uncertain.”

ASCO and Google Cloud set forth a vision for using AI to modernize health care and advance oncology

KRAS pioneer and Stephenson Prize winner Frank McCormick aims to prevent all KRAS cancers with a pill

Lazarex Cancer Foundation set to close its doors Dec. 31Can health nonprofits survive in the current environment?

ASCO report shows decrease in the number of oncologists relative to aging population

Trump backs off the 100% pharma tariffs ultimatum

Never miss an issue!

Login

The Directors: Steven Artandi and Eric Winer on how looming policy changes “reverberate” through oncology
“Even when funding gets restored and if the H-1B visa threat doesn’t materialize, it creates an environment where especially young people become uncertain.”

Lazarex Cancer Foundation set to close its doors Dec. 31
Can health nonprofits survive in the current environment?